Navigation Links
Adeona to Raise $3.5 Million in Registered Direct Offering
Date:4/7/2011

ANN ARBOR, Mich., April 7, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that it has executed an agreement for the sale of 1,688,782 shares of its common stock at approximately $2.0725 per share to a new institutional investor in a registered direct offering for $3.5 million in gross proceeds. The investor will also receive warrants to purchase approximately 844,391 shares of common stock at an exercise price of $2.0725 per share. The warrants are exercisable upon issuance for a period of 13 months from the closing date.  If exercised for cash, the warrants are expected to generate up to an additional $1.75 million in proceeds to Adeona.

"In addition to funding the continued development of our reaZin™ zinc-based medical food product candidate for Alzheimer's disease and our Trimesta drug product candidate for the treatment of multiple sclerosis, this financing will also allow us to explore new opportunities," stated James S. Kuo, M.D., M.B.A., Adeona's Chairman and CEO.

The offering is expected to close on or before April 11, 2011, subject to customary closing conditions, including approval by the NYSE AMEX. The net proceeds of approximately $3.25 million will be used for general corporate purposes, including conducting operations and advancing our clinical development programs.

Chardan Capital Markets acted as the sole placement agent for this transaction.

The shares and warrants are being offered in a registered direct offering under the Company's effective shelf registration statement previously filed on Form S-3 with the Securities and Exchange Commission (SEC).  This offering will be made by means of a prospectus supplement and the accompanying base prospectus, copies of which may be obtained, when available, from www.sec.gov.

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Adeona Pharmaceuticals, Inc.

Adeona is a pharmaceutical company developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Currently, Adeona is developing the following product candidates: a prescription medical food for Alzheimer's disease, and drugs for multiple sclerosis, fibromyalgia and age-related macular degeneration. For more information, please visit Adeona's website at www.adeonapharma.com.

This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the timing and results of our clinical study and our ability to successfully develop products with superior benefits. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, the availability of financial and other resources and the allocation of resources among different potential uses, unanticipated expenses that could cause a change in our use of proceeds, a failure of our clinical trials to be completed on time or to achieve desired results, a failure of our clinical reference laboratory to continue to grow and achieve revenue or a failure by us or our strategic partners to successfully commercialize products and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2010 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.


'/>"/>
SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Adeona Reports 2010 Year End Financial Results
2. Adeona to Host 2010 Year End Investor Conference Call
3. Adeonas Multiple Sclerosis Trial Receives $409,426 Grant
4. Adeona Receives Excellence in Science & Technology Award
5. Adeona Appoints George J. Brewer, M.D., Senior Vice President of Research & Development
6. Adeona Mourns the Passing of David A. Newsome, M.D., Senior Vice President of Research & Development
7. Adeonas Alzheimers Disease Pivotal Clinical Study Results Abstract Accepted for Presentation at the American Academy of Neurologys 63rd Annual Meeting
8. Adeona to Raise $4 Million in Registered Direct Offering
9. Adeona to Host Investor Day on Zinc Deficiency in Alzheimers Disease
10. Adeona to Present at OneMedForum San Francisco 2011 Conference
11. Adeona Acquires Access to Clinical Data Supporting Oral Zinc for Prevention of Infections in the Elderly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... May 23, 2016 Non-invasive diagnostic ... of multiple diseases; ,Technology to be presented at Yissum’s ... Yissum Research Development Company of the Hebrew University of ... research agreement with Aurum Ventures MKI, the technology investment arm ... a new diagnostic approach for early detection of multiple ...
(Date:5/22/2016)... May 23, 2016 DS ... anti-fibrotic and anti-inflammatory compound DS102 in chronic obstructive ... non-alcoholic steatohepatitis (NASH) patients. Recent DS ... in lung tissue and has bronchodilatory, anti-inflammatory and ... administration. The Company will publish further detail on ...
(Date:5/20/2016)... ReportsnReports.com adds "Plaque Psoriasis ... research report with comprehensive information on the therapeutic ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
Breaking Medicine Technology:
(Date:5/24/2016)... Orion, Clarkston Michigan (PRWEB) , ... May 24, ... ... new Certified Nurse Midwife, Roberta Jordan. , Roberta Jordan is a Certified ... degree from Grand Valley State University and then went on to complete her ...
(Date:5/24/2016)... Indianapolis, IN (PRWEB) , ... May 24, 2016 ... ... employee benefits advisory organization, is pleased to welcome new Partner Firm Austin & ... a personalized, consultative approach to insurance, employee benefits, HR consulting, benefits technology, and ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Center at Sentara Northern Virginia Medical Center located in Woodbridge, VA. The ... surgical services into a single site. , The new 2 story building houses ...
(Date:5/24/2016)... ... May 24, 2016 , ... Mental health watchdog Citizens Commission on Human ... renowned professor of psychiatry Thomas Szasz, is continuing its protest against the use of ... exhibit in Atlanta, Georgia. The opening of the exhibit follows CCHR’s recent protest at ...
(Date:5/24/2016)... ... May 24, 2016 , ... Loma Linda University Health ... adult hospital and expanded Children’s Hospital. Over 3,000 people looked on as the shovels ... out the event photo slidehsow. , During the program, Richard H. Hart, MD, ...
Breaking Medicine News(10 mins):